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Abstract
Economic evaluation (EE)/cost effectiveness analysis(CEA)
of healthcare programmes is an emerging area, yet the
resource base to apprehend EE/CEA is very limited in
Pakistan. This paper attempts to fill this gap by providing
a basic text in the field of EE with special reference to
Pakistan. We used four dimensional criteria (available,
relevant, complete and accurate) for reviewing the EE
contents in the locally available textbooks and reading
material on public health. We find CEA as core
competency and skill of medical doctors in
undergraduate medical curricula yet we could not find EE
contents in the recommended textbooks. We find that
economic evaluation entails two rules: both cost and
effectiveness should be included in the analysis, and there
must be a comparison of at least two drugs or medical
intervention. We describe EE/CEA in this article and
recommend that EE content should be included in the
medical and public health curriculum in Pakistan. 
Keywords: Economic Evaluation, Cost effectiveness
analysis, Healthcare Economics and organization.
Introduction
Economic Evaluation (EE) is well known method for
making clinical decision and health policyaide. In many
high income countries EE is a legal requirement for
approval of new medicines and medical devices.1 In low
and middle income countries (LMIC) EE is an emerging
area. Though EE is a core component of medical and
public health curriculum designed by Pakistan Medical
and Dental Council (PMDC)2 and College of Physician and
Surgeon (CPSP)3 yet EE contents are included in the
curriculum of only a few academic institutions.4,5 There
are limited locally available resources in this field.
Contents of EE covered only in a few books on public
health and community medicine and lack complete and
accurate information on EE.
This paper attempts to fill the gap in the academic
teaching of cost effectiveness analysis to the students
of medical and community medicine. We reviewed
locally available resources in the field of EE and
identifies gaps in them. We provide here the
appropriate definition, scope and types of EE with
examples from the published literature in this field from
Pakistan and elsewhere. 
Methods
We reviewed the medical curriculum of PMDC and
community medicine syllabus of CPSP and locally available
textbooks and reading material on EE of the PMDC, CPSP
and few leading medical schools in Pakistan. A four
dimensional criteria was developed for this review i.e.
1. Is the EE content available?
2. Is the information on EE relevant to the local context? 
3. Is the information provided complete for
understanding the concepts of EE?
4. Is the available content on EE accurate?
The topic was referred as missing when the word/phrase
"economic evaluation or cost analysis, cost effectiveness
analysis, cost utility analysis and cost benefit analysis" is
not mentioned anywhere in the book. If encountering a
topic which is addressing other areas instead of the
intended EE/CEA, we defined that as "irrelevant". We
defined "incomplete" if information of EE/CEA was not
completely present or inadequately covered the topic. If a
topic/content on EE/CEA is misleading, we defined that
category as "inaccurate."
In order to find appropriate content of EE we reviewed
published literature and book material on the subject
matter. We reviewed five widely recommended text
books by PMDC, CPSP and many leading medical
schools in the country for the contents of EE. These
include Public Health and Community Medicine,4
Preventive and Social Medicine,5 Fundamentals of
Preventive Medicine,6 Foundations of Community
Medicine7 and Text book of Public Health and
Community Medicine.8
A thorough literature search was carried out to find
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published literature on CEA on healthcare intervention
in Pakistan. We searched Google Scholar and PubMed
using the terms economic evaluation, cost analysis,
cost of services, cost effectiveness analysis, cost utility
analysis and cost benefit analysis with term Pakistan.
We used an open search strategy by applying no
restriction on publishing year, types of articles and
language of the article in our search strategy. 
Findings
We found that using CEA for clinical decision making as a
core competency and skill required from the medical
graduates in the medical curriculum of the PMDC.2 Cost
effective analysis and cost benefit analysis of health
programmes and intervention was found to be the core
component of the syllabus of community medicine under
separate section on healthcare financing and economics.3
Our review of text books of public health and community
medicines revealed that the essential component of
economic evaluation was missing holistically from these
medical textbooks.  For instance, the textbook by Ilyas
and Khan et al4 does not address the topic of economic
evaluation at all. Some aspect of "cost" is covered under
the topic, "Financial Cost and Cost Aspects of Primary
Health Care (PHC)". The textbook by Park5 considers
EE/CEA as quantitative method based on behavioural
sciences. The information regarding economic evaluation
is somehow mentioned in the text but is either irrelevant
(e.g. Input-Output analysis) or inaccurate. Text book by
Shaikh (2009)6 considers the method of "cost-benefit
analysis (CBA)" as a "more promising tool" than CEA
however in health economics CEA and Cost utility analysis
are more common than CBA.9 The description on CEA in
Sheikh6 was misleading and did not highlight the core
components of CEA. Furthermore, none of the books
mentioned above depict the concepts of Health
Economics and Economic Evaluation in the local context
of Pakistan. 
Literature search on EE/CEA from Pakistan returned
twelve peer reviewed articles. Out of these, three articles
covered cost effectiveness analysis,10-12 five articles
provided costing of various services,13-17 two articles
provided the quality of life of the patient of hepatitis B
and quality of life of patient with hypertension in
Pakistan18,19 and one article provided expenditure of
family planning programme in Pakistan.20
We find three books as highly recommended text on
EE/CEA globally. These are Methods for the economic
evaluation of healthcare programmes,21 Cost
effectiveness of health and medicine22 and Economic
evaluation in healthcare:merging theory with practice.9
In addition, we find online resources on cost
effectiveness analysis in health care on the web portal of
International Society for Pharmacoeconomics and
Outcome research (ISPOR).23 Based on our review of
these resources in the following section we provide
nature, scope and types of economic evaluation used in
healthcare.
Nature and Scope of Cost Effectiveness
Analysis
The objective of EE/CEA is choosing the most efficient
programme among all available options on the basis of
their respective cost and respective effectiveness. Hence,
EE/CEA is a relative term which entails two rules; first both
cost and effectiveness should be included in the analysis
and second, there must be a comparison of a programme,
drug or medical intervention with at least one alternative.
For example we can only make a statement on cost
effectiveness of a poliomyelitis vaccination, if we have
accounted for its cost and effectiveness and compare it
with the cost and the effectiveness of an alternative
programme such as a rehabilitation programme for polio
related disability.
The appropriate term is "economic evaluation" with CEA
as one of its types. Other types of the economic
evaluation include cost benefit analysis (CBA), cost utility
analysis (CUA) and cost analysis.
We developed a chart classifying types of economic
analysis based on two rules discussed above.21 Studies if
comparing alternatives and taking into account both
costs and outcomes Boxes 1-3 in the Figure can be
categorized as full economic evaluations (Figure).
Difference Between Cost and Expenditure
An important starting point in EE is to distinguish
between cost and expenditure. Cost means the money
value of actual resource-use on a programme or
intervention.  Expenditure, on the other hand, is the
money spent by a programme or intervention. For
example article by Abbas and Khan, shows the cost of
USD 17 per couple of years protected (CYP) and cost of
USD 77 per woman served in the year 2005-06 by the
ministry of Population Welfare (MoPW).20 In fact they have
estimated expenditure per CYP and women served. Firstly
because expenditure by MoPW on capital goods such as
building, equipment, vehicles and even staff training that
would have been utilized even after 2005-06, is included
in their estimates. As a rule of thumb all capital costs
should be annutized and then included in the costs
estimates.  Moreover, expenditure on management and
stewardship related function may not be added in the
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cost of services delivery function of MoPW. 
A study on cost of primary healthcare provided PKR 295
cost per out-patient visit to a Basic Health unit in Pakistan
in the year 2005-06.13 By one patient served for a common
illness at BHU (USD 4.1) is far less costly than one woman
served at government family planning centre (USD 77).
However such comparison is misleading and might
undermine the efforts of ministry of population planning
as inefficient. Since the former13 is actual cost while the
latter20 is an expenditure. 
Other studies based on costing from Pakistan can best be
described as cost of illness or cost of service studies (Box
7 in the Figure).13,14,17
Types of Cost Effectiveness Analysis
Economic evaluation has four types. Except for cost
analysis, the other three types are considered as full
economic evaluations. In the following paragraphs the
types of economic evaluation are explained.
Cost Analysis/ Cost Description
Cost analysis is comparison of costs of two or more
programmes (Box 4 in the Figure). In such compassion
either the effectiveness is ignored or assumed to be
similar across the interventions included in the analysis.
Briggs and O'Briene24 (2001) discussed its irrelevance for
medical decision making.23 We explain cost description
with the help of case study 1.25
Case Study 1: What is the type of the following
economic evaluation?
Ostrowsky and Lippman et al (1985) provided economic
account of Montreal Thalassemia Disease Prevention
Programme. They compared the cost of prevention of
Thalassemia i.e. carrier screening and prenatal diagnosis
with treatment of Thalassemia i.e. diagnosis,
Splenectomy, Transfusion therapy and Chelation therapy.
They concluded that the cost of prevention of
Thalassemia is 3.51 times lower than cost of treatment of
Thalassemia.25
Answer: Though the title of the article suggests that it is a
cost benefit analysis yet it is cost analysis of two
programmes i.e. Box 4 in the Figure.
Cost Effectiveness Analysis (CEA)
Cost effectiveness analysis refers to the analysis in which
costs are compared with the outcomes measured in
natural units, such as "lowered levels of blood pressure",
J Pak Med Assoc
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Figure: Nature and scope of economic evaluation of health programs/intervention.
"ability to accurately diagnosis symptom" and "symptom-
free days", or some types of functional and emotional
ability scale etc (Box 1 in the Figure). Effectiveness
measured in this manner limits the comparison of
intervention across clinical areas. We explain this with the
help of a case study 2.10,11
Case Study 2. Is hypertension management is cost
effective than community based case management of
Tuberculosis.
Jafar and Islam (2012) provided cost effectiveness of
management of hypertension at a community in Pakistan.
They provided a cost per 1 mmHg drop in systolic blood
pressure. The authors concluded that combined home
health education plus trained GP is cost effective than
other interventions in the trial.11
Khan and Wally et al. (2002) provided cost effectiveness of
management of Tuberculosis (TB) through Directly
Absorbed Treatment Strategy (DOTS).10 The finding
suggested adding a community health worker to observe
the patient taking treatment, as a cost effective strategy
than the other strategies to treat TB.10
Answer: Interventions with a different set of goals and
outcomes cannot be compared. For example cost per mm
Hg drop in diastolic blood pressure cannot be compared
with cost per tuberculosis case management with DOTS
and community health worker.
Another limitation of CEA is the situation in which there
are more than one outcomes of a programne or
intervention. For instance comparing cost effectiveness of
home based versus care-as-usual for palliative care can
yield multiple outcomes such as lowering pain, increased
mobility and smooth dying process etc.
Cost Utility Analysis (CUA)
Cost Utility Analysis is type of economic evaluation in
which the outcome is measured in terms of survival
and quality of life (Box 2 in the Figure). CUA combines
life years gained as a result of a health programme with
some judgment on the quality of those life years. It is
this judgment element that is labelled utility. This
approach of using utility is not restricted to similar
clinical areas, but can be used to compare very
different health programmes in the same terms. For
example quality of life scores for Hepatitis B18 and
quality of life scored for hypertension19 can be
compared: which is otherwise not possible.
In cost utility analysis the outcomes are valued
according to their desirability.21 Quality Adjusted Life
Years (QALY) is a generic outcome measure which
combines quality and length of life into one arithmetic
product. Cost utility analysis using QLAYs as outcome
measure can potentially address the resource allocation
challenges with a given budget and thus is widely used
for health policy making.9 In case study 3 we explain
distinguish CEA and CUA.26
Case Study 3. What is the type of the following
economics evaluation?
Cost Utility Analysis  by Wiwanitkit (2006) on  the right
method for screening haemoglobin E among Thai
pregnant women compared the costs of four methods
of screening namely Red blood cell index
Determination, Application of mathematical Model
(based on RBC parameters), Dichloro-Phenol-Indo-
Phenol (DCIP) test and Haemoglobin electrophoresis.
The authors estimated cost of each test and compared
this with their respective utility as rate of ability to
accurately detect carriers of haemoglobin disorders in
pregnant women.26
Answer: This type of analysis is more appropriately
classified as cost effectiveness analysis rather than cost
utility analysis as the ability of the test to accurately
diagnose is the sensitivity of the test rather than the utility
derived from the test. In their analysis Griffin and Barber et
al (2007) provided a CUA with an appropriate
methodology to estimate quality and length of life: that is
comparable across interventions. They concluded the
CBAG is cost effective with GBP 22000 per QALY than
other intervention at the threshold of GBP 30000/QALY.27
Cost benefits analysis (CBA)
Cost Benefit Analysis is considered as the most
comprehensive and theoretically sound than other
forms of economic evaluation.  CBA seeks to place
monetary values on both the inputs (costs) and
outcomes (benefits) of health care, making it possible to
say that what a particular programme is worth selecting
without any external reference: in the sense that its
total benefits exceed its total costs (Box 3 in the Figure).
CBA enables comparisons to be made between
programmes in different areas of healthcare, even
outside the field of medicine, owing to its virtue of
converting benefit into monetary term. However, the
analysis may ignore important benefits that are
difficult to assign a monetary value (for instance relief
of anxiety). 
A recent practice on monetary valuation of outcomes is
placing a monetary value on one QALY. In the UK the
common threshold value of one QALY is British pound
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30000. Intervention with cost per QALY less than BP 30000
usually qualifies for NHS funding. In United States of
America (USA) this threshold is United States Dollar 50000
per QALYs. The World Health Organization recommends
three times per capita Gross Domestic Product (DGP) of a
country as a threshold value of one Disability Adjusted
Life Year (DALY).28
Incremental Analysis
Health policy relevant component of EE is the incremental
cost effectiveness ratio (ICER). Numerically this is the ratio
of difference in the costs of two programmes over
difference in effectiveness of these programmes i.e.
ICER= (C1-C2)/(E1-E2)
In the equation above C1 and C2 are the cost of
programme 1 and programme 2 and E1 and E2 are the
effectiveness of programme 1 and programme 2
respectively. The incremental analysis informs a policy
maker on a more pressing decision dilemma of "how
much does it cost incrementally for switching from
current programme to the cost effective programme.
Interpretation of ICERs is explained in case study 4.11
Case Study 4. Interpreting incremental cost
effectiveness ratios.
What is the policy interpretation of the ICER reported in
Jafer and Islam (2011) i.e. for management of
Hypertension that Household health education (HHE)
plus GP training is cost effective than control arm (care as
usual) with ICER of USD 23 per 1 mmHg drop in systolic
blood pressure.11
Answer: If a health policy maker replaces the usual
care of hypertension with HHE plus GP at the primary
care level, then each additional drop in one mmHg in
systolic blood pressure will cost the society an addition
of USD 23.
Limitations
In medical evidence results of clinical trials can be
applied for medical decision making across countries,
economic evaluation does not have this liberty. This
suggests that an intervention being cost effective than
another intervention in a country would not
necessarily be cost effective in other countries. One
most prominent example to refer here is the case of
comparing cost effectiveness of Coronary Artery
Bypassing Grafting (CABG) versus percutaneous
coronary intervention (PCI). The summary findings of
Stroupe and Morrison et al (2006) is that PCI is cost
effective than CABG in the patient population from
USA. On the other hand, findings by Griffith and Barber
et al (2006)27 concluded that CABG is cost-effective
than PCI in the United Kingdom settings.29 Besides
many differences in the methodology, patient
population and outcomes etc. applied in both the
papers the results are contradictory: indicating a key
limitation of EE.
Conclusion
In our explanation of economic evaluation of healthcare
programmes we focused on the scope and types of cost
effectiveness analysis. We demonstrated that there are
ambiguities and incompleteness in the locally available
books. We also demonstrated that such ambiguities and
incompleteness also exist in peer reviewed scientific
literature.
This article is one of the first steps to spread knowledge of
EE in Pakistan. However we recommend more systematic
efforts to ensure that EE contents are included and
properly taught at the medical and public health schools
in the country. 
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